Market Cap 891.98M
Revenue (ttm) 76.30M
Net Income (ttm) -122.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.81%
Debt to Equity Ratio 0.00
Volume 301,420
Avg Vol 469,842
Day's Range N/A - N/A
Shares Out 69.58M
Stochastic %K 47%
Beta 1.17
Analysts Strong Sell
Price Target $21.35

Company Profile

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform in...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 274 8744
Address:
108 Patriot Drive, Suite A, Middletown, United States
jimmythetulip
jimmythetulip Jun. 25 at 2:50 PM
$ZYME is there any sort of news or catalyst expected anytime soon?
1 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Jun. 24 at 1:13 AM
$ZYME stock is a complete turd and just beholden to a Jazz buyout at this point. Wtf is ecor doing accumulating this 💩. Hasn’t done shit in years
0 · Reply
twitofstock
twitofstock Jun. 16 at 4:21 PM
$ZYME $JAZZ Just updated the primary completion for Herizon-gae-01 trial from 2025-05-15 to 2025-10-15 does this mean that Ziihera is more efficient than they anticipated?
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Jun. 11 at 9:40 PM
$ZYME Shorts shorted another 400k shares may 15-may31. 7.2 mil shares short on a stock that is 95% held only a few million shares freely trade. Chart is breaking over the descending trendline going back to November With lots of upcoming catalysts
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Jun. 9 at 10:48 PM
$ZYME several large orders intraday large short started covering before the next push
1 · Reply
jimmythetulip
jimmythetulip May. 30 at 2:13 PM
$ZYME typical. Goes down on good news.
3 · Reply
maplelakeduckslayer
maplelakeduckslayer May. 30 at 1:30 PM
$ZYME Couple presentations coming up over the next month and EU approval should hit in june as well
1 · Reply
StocktwitsNews
StocktwitsNews May. 30 at 11:54 AM
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge $ZYME $IWM $VTI https://stocktwits.com/news/equity/markets/zymeworks-drug-gets-conditional-approval-for-biliary-tract-cancer-in-china/ch0Mun4RbMx
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 11:20 AM
$ZYME Zymeworks announces NMPA approval of zanidatamab in China Zymeworks announced that the National Medical Products Administration in China has approved zanidatamab for the treatment of patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer. The conditional approval marks the first and only1 dual HER2-targeted bispecific antibody approved for HER2-high expression BTC in China. Zymeworks' collaboration partner, BeOne Medicines Ltd., obtained the conditional approval under the terms of its Asia Pacific license and collaboration agreement with Zymeworks. Continued approval of this indication will depend on the verification of clinical benefit in the patient population through ongoing confirmatory trials.
0 · Reply
Boris_Badenov
Boris_Badenov May. 30 at 10:54 AM
$ZYME Zani approved in China for BTC. milestone payments and royalties to come. “$20 million milestone payment to be received from BeOne Medicines; Zymeworks remains eligible to receive up to $144 million in additional development and commercial milestones” ”Zymeworks is also eligible to receive tiered royalties of up to 19.5% of net sales in BeOne Medicine’s territories.” https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-nmpa-approval-zanidatamab-china-adults
1 · Reply
Latest News on ZYME
Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:00 PM EDT - 6 weeks ago

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript


Zymeworks: Poised For Growth With Platform Validation

Apr 28, 2025, 10:48 AM EDT - 2 months ago

Zymeworks: Poised For Growth With Platform Validation


Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 8:43 PM EST - 4 months ago

Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript


3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 5 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT JAZZ ONC XBI


Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 10:05 PM EDT - 8 months ago

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript


Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27, 2024, 2:47 PM EDT - 9 months ago

Zymeworks Approaching A Moment Of Truth With Zanidatamab


Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:58 PM EDT - 11 months ago

Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript


jimmythetulip
jimmythetulip Jun. 25 at 2:50 PM
$ZYME is there any sort of news or catalyst expected anytime soon?
1 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Jun. 24 at 1:13 AM
$ZYME stock is a complete turd and just beholden to a Jazz buyout at this point. Wtf is ecor doing accumulating this 💩. Hasn’t done shit in years
0 · Reply
twitofstock
twitofstock Jun. 16 at 4:21 PM
$ZYME $JAZZ Just updated the primary completion for Herizon-gae-01 trial from 2025-05-15 to 2025-10-15 does this mean that Ziihera is more efficient than they anticipated?
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Jun. 11 at 9:40 PM
$ZYME Shorts shorted another 400k shares may 15-may31. 7.2 mil shares short on a stock that is 95% held only a few million shares freely trade. Chart is breaking over the descending trendline going back to November With lots of upcoming catalysts
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Jun. 9 at 10:48 PM
$ZYME several large orders intraday large short started covering before the next push
1 · Reply
jimmythetulip
jimmythetulip May. 30 at 2:13 PM
$ZYME typical. Goes down on good news.
3 · Reply
maplelakeduckslayer
maplelakeduckslayer May. 30 at 1:30 PM
$ZYME Couple presentations coming up over the next month and EU approval should hit in june as well
1 · Reply
StocktwitsNews
StocktwitsNews May. 30 at 11:54 AM
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge $ZYME $IWM $VTI https://stocktwits.com/news/equity/markets/zymeworks-drug-gets-conditional-approval-for-biliary-tract-cancer-in-china/ch0Mun4RbMx
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 11:20 AM
$ZYME Zymeworks announces NMPA approval of zanidatamab in China Zymeworks announced that the National Medical Products Administration in China has approved zanidatamab for the treatment of patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer. The conditional approval marks the first and only1 dual HER2-targeted bispecific antibody approved for HER2-high expression BTC in China. Zymeworks' collaboration partner, BeOne Medicines Ltd., obtained the conditional approval under the terms of its Asia Pacific license and collaboration agreement with Zymeworks. Continued approval of this indication will depend on the verification of clinical benefit in the patient population through ongoing confirmatory trials.
0 · Reply
Boris_Badenov
Boris_Badenov May. 30 at 10:54 AM
$ZYME Zani approved in China for BTC. milestone payments and royalties to come. “$20 million milestone payment to be received from BeOne Medicines; Zymeworks remains eligible to receive up to $144 million in additional development and commercial milestones” ”Zymeworks is also eligible to receive tiered royalties of up to 19.5% of net sales in BeOne Medicine’s territories.” https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-nmpa-approval-zanidatamab-china-adults
1 · Reply
omiabtrades
omiabtrades May. 29 at 10:44 AM
$ZYME Monthly - this one looks better if it can clear above the pink circle getting a nice close over that 16.85 - 17$ range https://www.tradingview.com/x/wj5wbc1g Doing that can lead it to test the blue arrow within that trading range if the circle , I like 25-30$ as a price target on this one
0 · Reply
trading_momentum
trading_momentum May. 29 at 3:12 AM
$ZYME Monthly - this one looks better if it can clear above the pink circle getting a nice close over that 16.85 - 17$ range Doin that can lead it to test the blue arrow within that trading range if the circle , I like 25-30$ as a price target on this one It’s in an ascending channel but it’s coming from the bottom of bottoming out so this can be pretty bullish
0 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson May. 27 at 7:55 PM
$ZYME ill scoop more under 10, seems to be headed that way
0 · Reply
StocktwitsNews
StocktwitsNews May. 21 at 5:02 AM
TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy $ZYME https://stocktwits.com/news/equity/markets/td-cowen-initiates-zymeworks-buy-ziihera-blockbuster-biliary-tract-cancer/ch0ItX4RboU
0 · Reply
maplelakeduckslayer
maplelakeduckslayer May. 21 at 1:57 AM
$ZYME ecor bought more...analist buy recommendations...lets get the party started. Think the phase 1 presentations in june gonna be exciting
1 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson May. 20 at 6:06 PM
$ZYME whoa
0 · Reply
CHItraders
CHItraders May. 19 at 8:21 PM
$ZYME Zymeworks To Reveal New Preclinical Data For ZW1528, A Novel Il-4Rα X IL-33 Bispecific Molecule Designed To Address Respiratory Inflammation, At The American Thoracic Society International Conference Being Held May 18-21, 2025 In San Francisco, CA
0 · Reply
DonCorleone77
DonCorleone77 May. 19 at 8:20 PM
$ZYME Zymeworks presents new ZW1528 data at ATS conference Zymeworks announced the presentation of new preclinical data for ZW1528, a novel IL-4Ra x IL-33 bispecific molecule designed to address respiratory inflammation, at the American Thoracic Society International Conference being held May 18-21 in San Francisco, California. Key findings for ZW1528 include: high-affinity binding to both IL-33 and IL-4Ra and effective blockade of IL-4, IL-13, and IL-33 signaling at levels comparable to clinical benchmark monoclonal antibody controls. Suppression of both Type 2 and non-Type 2 responses in primary human immune cells of COPD patients in vitro. Efficacy in vivo in acute and chronic murine models of lung inflammation driven by house dust mites. Extended pharmacokinetics in rodent and non-human primate models, with incorporation of Fc extending half-life optimization. Biophysical stability at high concentration, supporting potential for subcutaneous administration.
0 · Reply
maplelakeduckslayer
maplelakeduckslayer May. 17 at 3:21 PM
0 · Reply
jdlman
jdlman May. 12 at 11:05 AM
$ZYME can we get some action here
0 · Reply
jdlman
jdlman May. 9 at 1:51 PM
$ZYME why is she jumping? Any news?
1 · Reply
maplelakeduckslayer
maplelakeduckslayer May. 8 at 8:18 PM
$ZYME earnings "beat"...two phase 1 presentations in june. Seeing some data on their wholly owned pipeline may be what this needs
2 · Reply